PHMB PharmaCom BioVet Inc (CE)

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce that their new Canine Cancer Treatment Centers will provide state-of-the-art cancer technologies to meet the growing demand for effective treatment of companion animals afflicted with lymphoma and other forms of cancer.

Concurrent with human trends for increasing life spans, companion animals are also living longer. According to a recent report by Tatjana Meerman, Publisher of Packaged Facts, Rockville, Maryland, "Pets are living longer because their owners are taking better care of them, both medically and nutritionally." The report continues by stating that the ever growing bond between pet owners and their companion animals means, "...an increased willingness among pet owners to do whatever it takes to keep their pets healthy and happy for as long as possible."*

However, in the face of this trend, there has been an alarming lack of adequate options for the treatment of cancer; the number one cause of death in companion dogs. Statistically, one in three dogs is diagnosed with cancer at some time in their life, and at least 50% of those dogs are likely to succumb. The primary reasons for these staggering statistics are 1) a major deficiency in canine cancer treatment facilities across the country and, 2) out-dated or inadequate cancer treatment methodologies available for canine cancers.

PharmaCom BioVet, Inc. founders, Gary and Sharon Berthold, experienced this tragedy first hand and decided to do something about it. As life-long dog lovers and breeders, the Bertholds lost two of their prize Siberian Huskies to cancer. In their search for remedies, they discovered a huge void in care centers and treatment options. That reality inspired them to not only fill the void, but to advance the cause of creating leading-edge treatment centers using the latest scientific breakthroughs in cancer treatment. Among these novel treatment programs are bone marrow transplant procedures and direct injection liquid Brachytherapy.

Teaming up with IsoTherapeutics Group, LLC of Angleton, Texas, PharmaCom BioVet, Inc. is poised to support research and help introduce novel cancer treatment methodologies into its canine cancer treatment centers, as well as to the veterinary marketplace as a whole. "Our ultimate goal is to eradicate cancer in companion animals. We are bringing together the brightest minds in cancer research and oncology treatment programs to fulfill this goal," stated Berthold of PharmaCom BioVet, Inc. "We are excited to join forces with companies like IsoTherapeutics Group, LLC and veterinary leaders across the country, in this endeavor to help companion animals not only live longer, but live healthier," concluded Berthold.

About PharmaCom BioVet, Inc.:

PharmaCom BioVet, Inc. is dedicated to advancing the veterinary care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the country. The purpose of these centers is to help prolong the quality of life for companion animals with cancer and pursue the potential for complete cure. These centers will also operate under the philosophy of providing a compassionate care environment for both companion animal patients and their owners. For more information, please visit our website www.PharmaComBioVet.com.

About IsoTherapeutics Group, LLC:

The mission of IsoTherapeutics Group, LLC is to develop novel diagnostic and therapeutic agents for the treatment of severe diseases. ITG both develops their own technologies as well as partners with other companies to help develop pharmaceuticals. Of special interest are radiopharmaceuticals for oncology. In house expertise includes synthetic organic chemistry, chelation chemistry, radiochemistry, diagnostic and therapeutic isotopes, conjugation chemistry, pharmacokinetics, and small animal research models. For more information, please visit our website www.isotherapeutics.com.

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

*Reference: Packaged Facts press release, Friday, October 10, 2008. Packaged Facts is a division of Market Research Group, Rockville, Maryland.

Contact: Market Ideas, Inc. 877-295-3981 ext. 2 info@marketideasinc.com